Latest healthtech and biotech deals
The largest from last week:
🇺🇸 Dispatch Health, in-home medical care provider, raised $330M in equity and debt financing.
🇺🇸 Fog Pharmaceuticals raised $178M in Series D. The company plans to enter phase 1 trials with its lead asset, FOG-001, a beta-catenin inhibitor, in mid-2023.
🇮🇳 Lenskart.com, D2C eyewear brand, raised $40M. The company boasts of serving more than 7M customers annually through its omnichannel shopping experience, which spans through online, mobile application, and stores.
Other notable deals from around the globe:
🇩🇪 Temedica, medical patient care startup, raised €25M in Series B. The startup has previously developed a bundle of apps for the German healthcare market (Pelvina, an online course for women to train the pelvic floor; Mineo, for back training; and Waya, an app that aids in weight loss). Now, the company appears to be focused more on the health insights side of things to offering a holistic understanding of patient’s care realities.
🇭🇺 Turbine AI, a company developing a cell behaviour simulation platform, raised €20M in Series A. Turbine will use the financing proceeds to drive its next generation, potential first-in-class programs targeting DNA Damage Repair.
Read up on all the latest health deals in Dealroom.co